^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
CYP2D6 mutation
i
Other names: YP2D6, P450-DB1, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, P450C2D, P450DB1, CYP2D, CPD6, CYP2DL1, CYPIID6, Cytochrome P450 Family 2 Subfamily D Member 6, Cytochrome P450 Subfamily IID (Debrisoquine Sparteine Etc. -Metabolising) Polypeptide 8 Pseudogene 2, Cytochrome P450 Subfamily II (Debrisoquine Sparteine Etc. -Metabolising) Polypeptide 7 Pseudogene 2, Cytochrome P450 Subfamily IID (Debrisoquine Sparteine Etc. -Metabolizing) Polypeptide 6, Cytochrome P450 Family 2 Subfamily D Polypeptide 7 Pseu
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
over1year
COSMIC Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers. (PubMed, J Pharmacol Exp Ther)
We found it likely that many of these mutations would alter enzyme function, leading to changes in drug metabolism in the tumor. We provide a basis for predicting the likelihood of a patient carrying these mutations to identify patients who may benefit from a precision medicine approach to drug selection and dosing.
Journal
|
CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6)
|
CYP2D6 mutation
Share via
